News & Updates

Treatment with deuruxolitinib, an oral Janus kinase 1/2 inhibitor, resulted in significant hair regrowth on the scalp for 24 weeks among patients with severe alopecia areata (AA), according to the two phase III THRIVE-AA1 and -AA2 trials presented at AAD 2026.

The results of the phase III Bax24 trial underpin the efficacy of baxdrostat, a selective aldosterone synthase inhibitor (ASI), for the treatment of uncontrolled or resistant hypertension (HTN).

Patients with long COVID may derive benefits from treatment with fluvoxamine, which has been shown to reduce fatigue and improve quality of life (QoL) in a study. The use of metformin, on the other hand, shows no significant advantage.